To the extent feasible, report adverse events to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: www.NovavaxMedInfo.com ...

The European Commission has approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373), following a positive opinion for a full authorization from the Committee for Medicinal Products for Human ...

In participants who received Nuvaxovid (n=17,184), there were 18 cases of mild COVID-19 and 0 cases of moderate or severe COVID-19 compared with 64 cases of mild, 8 cases of moderate, and 4 cases ...

Full authorization of prototype enables rapid authorization of updated Novavax COVID-19 vaccines in futureGAITHERSBURG, Md., Oct. 18, 2023 /PRNews ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Jun. 23, 2022 4:01 PM ET Novavax, Inc. (NVAX) ...

GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious ...

The FDA’s approval of Nuvaxovid™, which is not based on mRNA technology, has triggered a milestone payment of $175 million to Novavax from its collaborator Sanofi.

The EUL has been granted for the Nuvaxovid COVID-19 Vaccine, a novel recombinant, adjuvanted SARS-CoV-2 rS vaccine, which is to be marketed by Novavax in Europe and other markets.

Novavax knows it has some tough competition—Pfizer and Moderna's vaccines dominate the U.S. market—but the small biotech is eyeing certain market niches: The "vaccine hesitant" who might be ...

The commission authorized Nuvaxovid after a recommendation issued on Monday by the European Medicines Agency. In a statement, Novavax said that it expected initial doses to arrive in Europe in ...